Matthew K. Szot - 29 Dec 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Chief Financial Officer
Signature
/s/ Matthew K. Szot
Issuer symbol
CVKD
Transactions as of
29 Dec 2025
Net transactions value
-$69,233
Form type
4
Filing time
31 Dec 2025, 16:05:19 UTC
Previous filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Szot Matthew K Chief Financial Officer C/O CADRENAL THERAPEUTICS, INC.,, 822, A1A NORTH, SUITE 306, PONTE VEDRA, /s/ Matthew K. Szot 31 Dec 2025 0001401385

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVKD Common Stock Sale $69,233 -9,933 -100% $6.97 0 29 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.